Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seagen Inc.    SGEN

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen : to Host Virtual R&D Day on November 16, 2020

11/02/2020 | 08:03am EST

Seagen Inc. (Nasdaq: SGEN) announced today that it will host a virtual R&D day for investors and analysts on Monday, November 16, 2020 beginning at 10:00 a.m. Eastern Time. The program will include a presentation by members of Seagen leadership on the broad clinical development of the Company’s marketed products, ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv) and TUKYSA® (tucatinib), and its deep pipeline of innovative therapies for cancer.

Access to the event will be available at the Company’s website www.seagen.com in the Investors section. A replay will be archived on the Company’s website following the live presentation.

About Seagen

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.


© Business Wire 2020
All news about SEAGEN INC.
01/15SEAGEN : BofA Securities Upgrades Seagen to Buy from Neutral, Sets $215 Price Ta..
MT
01/07SEAGEN : to Host Conference Call and Webcast Discussion of Fourth Quarter and Fu..
BU
2020SEAGEN : Registers Mixed-Securities Shelf Offering
MT
2020SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020SEAGEN : to Present at the J.P. Morgan Healthcare Conference
BU
2020SEAGEN : Announces Positive CHMP Opinion for TUKYSA for the Treatment of Patient..
AQ
2020Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors
AQ
2020SEAGEN : Says European Regulatory Committee Recommends Approval of Tukysa in Bre..
MT
2020SEAGEN : Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatme..
BU
2020Boehringer gets into 'guided-missile drugs' with $1.5 billion deal for NBE
RE
More news
Financials (USD)
Sales 2020 2 163 M - -
Net income 2020 598 M - -
Net cash 2020 1 943 M - -
P/E ratio 2020 54,4x
Yield 2020 -
Capitalization 32 583 M 32 583 M -
EV / Sales 2020 14,2x
EV / Sales 2021 16,6x
Nbr of Employees 1 605
Free-Float 99,4%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 198,71 $
Last Close Price 180,12 $
Spread / Highest target 41,0%
Spread / Average Target 10,3%
Spread / Lowest Target -23,4%
EPS Revisions
Managers and Directors
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Robert J. Lechleider Senior Vice President-Clinical Development
Roger D. Dansey Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SEAGEN INC.2.84%32 583
MODERNA, INC.40.71%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.2.15%35 090
HANGZHOU TIGERMED CONSULTING CO.,LTD18.50%25 245